
Camallergy
camallergy.com
Camallergy – short for Cambridge Allergy Ltd – is a biopharmaceutical company spun out from Cambridge University Hospitals that provides innovative treatments for the millions of people who live with food allergies. Camallergy’s lead product, CA002, is an oral immunotherapy for the treatment of peanut allergy that provides protection to patients within 14 weeks of therapy. It achieved best-in-class results in over 300 children treated in a phase 2 trial. The key to this success is a combination of the natural compound used in the treatment and Camallergy’s patented treatment regimen that creates a win/win/win scenario: it’s more effective, safer, and easy to take. Allergy physician key opinion leaders strongly prefer this medicine over the current
options. The company’s IND is accepted by the FDA for phase 3 trials initiating in Q1 2023